Rituximab in refractory chronic inflammatory demyelinating polyneuropathy

Suraj A. Muley, Bill Jacobsen, Gareth Parry, Uzma Usman, Erik Ortega, David Walk, Jeff Allen, Mamatha Pasnoor, Matthew Varon, Mazen M. Dimachkie

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


Introduction: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a disorder in which early effective treatment is important to minimize disability from axonal degeneration. It has been suggested that some patients with CIDP may benefit from rituximab therapy, but there is no definitive evidence for this. Methods: Baseline and post–rituximab-therapy neuromuscular Medical Research Council (MRC) sum scores, Inflammatory Neuropathy Cause and Treatment (INCAT) disability score, and functional status were assessed in 11 patients with refactory CIDP. Results: The MRC sum score, INCAT disability score, and functional status improved in all patients after rituximab therapy. Discussion: Our study provides evidence of the efficacy of rituximab therapy in at least some patients with CIDP. A placebo-controlled study to assess the effectiveness of rituximab therapy in CIDP with and without nodal antibodies is required to identify disease markers that predict responsiveness.

Original languageEnglish (US)
Pages (from-to)575-579
Number of pages5
JournalMuscle and Nerve
Issue number5
StatePublished - May 1 2020

Bibliographical note

Publisher Copyright:
© 2020 Wiley Periodicals, Inc.


  • CIDP
  • neuropathy
  • refractory
  • rituximab
  • treatment

PubMed: MeSH publication types

  • Journal Article


Dive into the research topics of 'Rituximab in refractory chronic inflammatory demyelinating polyneuropathy'. Together they form a unique fingerprint.

Cite this